Changes in U.S. Prescribing Patterns of Menopausal Hormone Therapy, 2001–2003
- 1 July 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 108 (1), 33-40
- https://doi.org/10.1097/01.aog.0000220502.77153.5a
Abstract
In 2002, the combination estrogen–progestin hormone therapy (HT) treatment arm of the Women’s Health Initiative was terminated early because cardiovascular and cancer risks were identified, while the estrogen-only therapy (ET) arm of this trial continued. We investigated hormone therapy prescription practice changes between 2001 and 2003 to explore the effects of the clinical trial results. Data were obtained from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey for the years 2001 through 2003. These nationally representative surveys sample medical encounters in nonfederally employed physician’s offices and outpatient departments of nonfederal short-stay and general hospitals. The proportion and rate of visits with ET and HT prescriptions were calculated. Logistic regression was used to estimate change over time accounting for patient and provider characteristics. Between 2001 and 2003, the number of visits with menopausal hormone prescriptions fell from 26.5 million to 16.9 million. Almost three-quarters of hormone visits were for ET prescriptions. The decrease in the rate of visits was slightly larger for HT prescription visits (44%) than ET prescription visits (35%). The rate of decline was highest among women 50 years of age and over. After controlling for covariates, there was no significant difference in the decline by hormone type. These nationally representative data indicate substantial declines in menopausal hormone prescriptions coinciding with clinical trial results on HT. These declines occurred among all types of therapy and patient characteristics. II-3Keywords
This publication has 18 references indexed in Scilit:
- Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women’s Health InitiativePublished by American Medical Association (AMA) ,2004
- National Use of Postmenopausal Hormone TherapyPublished by American Medical Association (AMA) ,2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Cardiovascular Disease Outcomes During 6.8 Years of Hormone TherapyJAMA, 2002
- Hormone replacement therapy (HRT)— risks and benefitsInternational Journal of Epidemiology, 2001
- Hormone Replacement Therapy and CognitionJama-Journal Of The American Medical Association, 2001
- Low rates of hormone replacement in visits to United States primary care physiciansAmerican Journal of Obstetrics and Gynecology, 1997
- Use of Postmenopausal Hormone Replacement Therapy: Estimates from a Nationally Representative Cohort StudyAmerican Journal of Epidemiology, 1997
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991